NADA™ and ALGO™
Rapid Capture and Recovery of Nucleic Acids
Entropix has created a novel, rapid, solvent-free, cost-effective, safe and sustainable technology for nucleic acid capture and recovery, known as NADA™ (or Nucleic Acid Depletion Agent).
NADA™ has been developed specifically for the rapid removal of extraneous or contaminating nucleic acid, whilst ALGO™ is used for the recovery and purification of target nucleic acid. Both technologies have been validated by extensive testing in our own labs and with independent expert partners.
Through rigorous testing, we have verified that NADA™ and ALGO™ address and overcome the limitations of existing methods, such as leading commercial kits, which can be slow, unreliable and expensive. The technology has numerous potential applications in diagnostics, pharmaceuticals, forensics, recombinant protein production, aptamers, oligonucleotides and molecular biology research, covering both DNA and RNA.
In addition to the potential use of NADA™ and ALGO™ in reagents and kits, the speed and simplicity of the methods are ideal for automated instruments and large industrial processes.
NADA™ - Separation and Capture
- NADA™ is an aqueous formulation that can be added to solutions containing nucleic acids, forming a precipitate with the nucleic acid which can be separated by centrifugation or filtration in less than 1 minute.
- A very low concentration of NADA™ successfully captures the nucleic acid and achieves highly effective removal.
- More than 3 times total yield of genomic DNA (gDNA) recovered in testing using NADA™ compared with leading commercial kit.
- Any accompanying proteins retain activity after DNA removal using NADA™.
ALGO™- Recovery and Purification
- Once captured, the nucleic acid can be recovered with high yield and purity using the ALGO™ aqueous formulation.
- The biological function and sequence of the nucleic acid are unaffected by the recovery process – including transformation, amplification/PCR and ligation.
NADA™ and ALGO™ Enquiries
Further technical details are available under CDA along with demonstrations of the technology at customer premises.
Expressions of interest should be made to Dr Rob Rule, CEO at Entropix Ltd: [email protected] or +44(0)7917 584 354.
